Tocilizumab therapy in individuals with COVID‐19 infection and hyperinflammatory state

Míreanna Comhchosúla

• The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial
  le: Cotter, Aoife, et al.
  Foilsithe: (2020)
• The COVIRL-001 Trial: A multicentre, prospective, randomised trial comparing standard of care (SOC) alone, SOC plus hydroxychloroquine monotherapy or SOC plus a combination of hydroxychloroquine and azithromycin in the treatment of non- critical, SARS-CoV-2 PCR-positive population not requiring immediate resuscitation or ventilation but who have evidence of clinical decline: A structured summary of a study protocol for a randomised controlled trial
  le: Feeney, Eoin, et al.
  Foilsithe: (2020)
• Remote monitoring of oxygen saturation in individuals with COVID-19 pneumonia
  le: O'Carroll, Orla, et al.
  Foilsithe: (2020)
• Prevalence of comorbid asthma in COVID-19 patients
  le: Butler, Marcus W., et al.
  Foilsithe: (2020)
• Successful treatment of severe COVID-19 pneumonia and hyperinflammatory syndrome with tocilizumab
  le: Gentile, Giorgio, et al.
  Foilsithe: (2021)